Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Year range
1.
Chinese Medical Journal ; (24): 2665-2673, 2020.
Article in English | WPRIM | ID: wpr-877883

ABSTRACT

BACKGROUND@#Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.@*METHODS@#This study was a 52-week, multicentre, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 trial. A sub-population of study participants (≥18 years) of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab, or placebo. The co-primary endpoints were psoriasis area severity index (PASI) 75 and Investigator's Global Assessment (IGA) 0/1 at Week 12.@*RESULTS@#A total of 441 Chinese patients were enrolled in this study. Co-primary outcomes were achieved; 300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75 (97.7% and 87.2% vs. 3.7%, respectively; P < 0.001), and IGA 0/1 (82.3% and 69.7% vs. 2.7%; P < 0.001) at Week 12. Treatment efficacy was maintained until Week 52. There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period.@*CONCLUSION@#Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.@*TRIAL REGISTRATION@#ClinicalTrials.gov, NCT03066609; https://clinicaltrials.gov/ct2/show/record/NCT03066609.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , China , Double-Blind Method , Humans , Psoriasis/drug therapy , Severity of Illness Index , Treatment Outcome
2.
Article in Chinese | WPRIM | ID: wpr-712976

ABSTRACT

[Objective] To determine the efficacy and safety of local injections of botulinum toxin A in the treatment of androgenetic alopecia.[Methods] 72 male patients were randomly into botulinum toxin An group (n=35) and the control group (n=37),the treatment time was 6 months.All the patients were photographed and evaluated,before the treatment,and 3 months and 6 months.[Results] After the treatment of half a year,a good result was observed,the hair density in the treatment group was higher after 3months and 6 months than before the treatment (P<0.05),but there was no difference between the after 3months and 6 months (P>0.05),the hair density in the control group was higher after 6 months than before the treatment and after 3 months (P<0.05),but there was no difference between the after 3 months and before the treatment (P>0.05);but there was no difference between the after 3 months and 6 months (P>0.05);After 6 months,the effective ratio and in two group were 91.4% and 86.5% in treated group,it showed no significant difference (P>0.05) [Conclusion] the treatment of local injections of botulinum toxin A has a marked effect on androgenetic alopecia,it is safe and effective.

3.
Article in Chinese | WPRIM | ID: wpr-712928

ABSTRACT

[Objective]To determine the efficacy and safety of 1064nm Q-switched laser combined with drug therapy in the treatment of mild to moderate rosacea.[Methods]73 patients with mild to moderate rosacea were divided into two groups randomly.The treatment group including 37 patients were treated with Q-switched laser combined with drug thera-py,the control group including 36 patients were treated with drug therapy only.Efficacies and safety were evaluated 6 and 9 weeks after the treatments.[Results]A mean reduction in lesion count was observed,statistically significance differenc-es in effectiveness were found among each group(P<0.05),the effective ratio was 83.8% in treated group,of which was 61.1% in control group,it showed significant difference between these two groups(P<0.05). There was no side effect.[Conclusion]1 064 nm Q-switched laser combined with drug therapy has a marked effect on mild to moderate rosacea,it is safe and effective,better than simple drug treatment.

4.
Article in Chinese | WPRIM | ID: wpr-251689

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the expression of secreted frizzled-related protein 1 (SFRP1), β-catenin and E-cadherin in colorectal carcinoma and its clinicopathological significance.</p><p><b>METHODS</b>The expression of SFRP1, β-catenin and E-cadherin mRNA and protein in tumor and pericancerous tissue samples from 60 cases of colorectal cancer was assayed by reverse-transcription PCR and immunohistochemistry, respectively. The correlation of their expression with clinicopathological factors of colorectal cancer was analyzed.</p><p><b>RESULTS</b>In 52/60 cases the relative mRNA expression of SFRP1 in cancer tissue and pericancerous tissue was 0.4837±0.1532 and 0.7170 ±0.1830; for β-catenin was 0.9293± 0.3705 and 0.6469±0.3166; and for E-cadherin was 0.5556±0.2535 and 0.9422±0.2372 (P<0.01), respectively. SFRP1 mRNA expression was associated with lymphatic metastasis (P<0.05). The positive rate of SFRP1 in colorectal cancer was 31.67% (19/60), and was significantly lower than that in pericancerous colorectal mucosa (75.00%, 45/60). No relationship between SFRP1 protein expression and clinical pathology was found. Abnormal expression rates of β-catenin and E-cadherin in colorectal cancer were 75.00% (45/60) and 58.33% (35/60), respectively, which were significantly higher than that in pericancerous colorectal mucosa (1.67% and 6.67%), respectively. Abnormal β-catenin and E-cadherin expression was associated with tumor differentiation, lymphatic metastasis and Duke's staging. SFRP1 protein expression was negatively correlated with β-catenin and E-cadherin expression (r=-0.517, -0.442, Ps<0.01).</p><p><b>CONCLUSION</b>Down-regulation of SFRP1 in colorectal cancer may cause abnormal Wnt signaling and induce abnormal β-catenin and E-cadherin expression, indicating that SFRP1 might be involved in the development and progression of colorectal cancer, and could be a novel therapeutic target for colorectal cancer.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Cadherins , Metabolism , Colorectal Neoplasms , Metabolism , Female , Humans , Intercellular Signaling Peptides and Proteins , Metabolism , Lymphatic Metastasis , Male , Membrane Proteins , Metabolism , Middle Aged , beta Catenin , Metabolism
SELECTION OF CITATIONS
SEARCH DETAIL